Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution. Kennedy DA. PLoS Biol 2026;24:e3003701.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kennedy DA. Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution. PLoS Biol 2026;24:e3003701.
PMID: 41774743